The National Science Foundation (NSF) Cooperative Agreement award with the CFDA number 47.084 for the "NSF Technology, Innovation, and Partnerships" program provides $984,381 to Cobio Diagnostics Inc. to expand a novel diagnostic tool that allows rapid, direct-from-specimen testing for bloodstream infections. The project aims to develop new tests for identifying and determining antimicrobial susceptibility of key multidrug-resistant bacterial pathogens (ESKAPE pathogens) within 5 hours, in contrast to the 18-72 hours required by current standard-of-care approaches. The technology utilizes bacteriophage mixtures to quickly produce identification and phenotypic antibiotic resistance data, which can help physicians make more precise treatment decisions and combat the rise of antimicrobial resistance. This award builds upon Cobio Diagnostics' previous work funded through NSF SBIR grants and NIH grants totaling over $3 million, demonstrating the company's expertise in phage-amplified diagnostic technologies. The project period runs from September 1, 2024 to August 31, 2026.
Generated 3/4/25, 8:14 AM